Send to

Choose Destination
BMJ. 2019 Apr 4;365:l1141. doi: 10.1136/bmj.l1141.

Medicinal use of cannabis based products and cannabinoids.

Freeman TP1,2,3,4, Hindocha C3,4,5, Green SF4, Bloomfield MAP3,4,5,6,7.

Author information

Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, UK.
National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
Clinical Psychopharmacology Unit, Research Department of Clinical, Educational & Health Psychology, University College London, UK.
Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Faculty of Brain Sciences, University College London, UK.
NIHR University College London Hospitals Biomedical Research Centre, University College Hospital, London, UK.
Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Imperial College London, UK.
The Traumatic Stress Clinic, St Pancras Hospital, Camden & Islington NHS Foundation Trust, London, UK.
[Indexed for MEDLINE]
Free full text

Conflict of interest statement

Competing interestsThe BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: TPF was funded by a senior academic fellowship from the Society for the Study of Addiction (SSA). MAPB is funded by a UCL Excellence Fellowship. MAPB, SFG, and CH are supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. The views expressed here are those of the authors, and do not reflect those of the SSA, the University of Bath, UCL, or NIHR. The funders had no role on the planning, researching, or writing of this report or in the decision to submit it for publication. Further details of The BMJ policy on financial interests is here:

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center